modified FOLFIRINOX + gemcitabine

Modified FOLFIRINOX + gemcitabine is a combination chemotherapy regimen used primarily in the treatment of pancreatic cancer. Modified FOLFIRINOX consists of four drugs—folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin—administered at reduced doses to improve tolerability compared to standard FOLFIRINOX. Gemcitabine is a nucleoside analog that inhibits DNA synthesis. This combination may be considered for patients with advanced or unresectable pancreatic cancer, particularly after progression on first-line therapy or in specific clinical trial settings. The mechanism of action involves multiple pathways targeting DNA synthesis and repair, leading to inhibition of tumor cell proliferation and survival[1][2][4][5].

Other names

modified FOLFIRINOX plus gemcitabinemFOLFIRINOX + gemcitabine